Get access

Comparison of animal-derived surfactants for the prevention and treatment of respiratory distress syndrome in preterm infants

  • Protocol
  • Intervention

Authors


Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To compare the effect of administration of different animal-derived surfactant extracts on the risk of mortality, chronic lung disease, and other morbidities associated with prematurity in preterm infants at risk for or having RDS.

Comparisons:

Prevention studies

  1. Bovine lung lavage surfactant extract (calfactant, CLSE (BLES) or SF-RI 1 (bovactant)) versus modified bovine minced lung surfactant extract (beractant or surfactant TA).

  2. Bovine lung lavage surfactant extract (calfactant, CLSE (BLES) or SF RI 1 (bovactant)) versus porcine minced lung surfactant extract (poractant alfa).

  3. Bovine lung lavage surfactant extract (calfactant, CLSE (BLES) or SF-RI 1 (bovactant)) versus Porcine lung lavage surfactant (surfacen).

  4. Modified bovine minced lung surfactant extract (beractant or surfactant TA) versus porcine minced lung surfactant extract (poractant alfa).

  5. Modified bovine minced lung surfactant extract (beractant or surfactant TA) versus porcine lung lavage surfactant (surfacen).

  6. Porcine minced lung surfactant extract (poractant alfa) versus porcine lung lavage surfactant (surfacen).

Treatment studies

  1. Bovine lung lavage surfactant extract (calfactant, CLSE (BLES) or SF-RI 1 (bovactant)) versus modified bovine minced lung surfactant extract (beractant or surfactant TA).

  2. Bovine lung lavage surfactant extract (calfactant, CLSE (BLES) or SF RI 1 (bovactant)) versus porcine minced lung surfactant extract (poractant alfa).

  3. Bovine lung lavage surfactant extract (calfactant, CLSE (BLES) or SF-RI 1 (bovactant)) versus Porcine lung lavage surfactant (surfacen).

  4. Modified bovine minced lung surfactant extract (beractant or surfactant TA) versus porcine minced lung surfactant extract (poractant alfa).

  5. Modified bovine minced lung surfactant extract (beractant or surfactant TA) versus porcine lung lavage surfactant (surfacen).

  6. Porcine minced lung surfactant extract (poractant alfa) versus porcine lung lavage surfactant (surfacen).

Subgroup analyses

  1. Gestational age:

    1. prevention trials: infants born at < 28 weeks' gestation;

    2. treatment trials: infants born at < 30 weeks' gestation.

  2. Surfactant dosage (initial dose < 100 mg/pL).

  3. Surfactant dosing schedule (single dose, multiple dose).

  4. For treatment trials: disease severity.

  1. prevention trials: infants born at < 28 weeks' gestation;

  2. treatment trials: infants born at < 30 weeks' gestation.

Moderate to severe respiratory disease (moderate to severe disease defined as need for assisted ventilation and supplemental oxygen concentration greater than 40% necessary to maintain adequate oxygenation).